Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.30
-0.06 (-0.45%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 15,368 | 14,654 | 17,277 | 17,302 | 24,192 |
Short-Term Investments | 72,446 | 43,254 | 44,050 | 44,496 | 20,173 |
Cash & Short-Term Investments | 87,814 | 57,908 | 61,327 | 61,798 | 44,365 |
Cash Growth | 51.64% | -5.58% | -0.76% | 39.29% | 28.71% |
Accounts Receivable | 101,219 | 90,420 | 80,298 | 72,485 | 66,764 |
Inventory | 76,531 | 71,085 | 63,552 | 48,670 | 50,884 |
Other Current Assets | 36,411 | 30,699 | 42,876 | 21,302 | 15,810 |
Total Current Assets | 301,975 | 250,112 | 248,053 | 204,255 | 177,823 |
Net Property, Plant & Equipment | 115,930 | 97,761 | 75,997 | 66,294 | 61,665 |
Other Intangible Assets | 105,059 | 96,803 | 36,951 | 30,724 | 27,011 |
Goodwill | 12,893 | 11,810 | 5,501 | 5,474 | 5,473 |
Long-Term Investments | 16,368 | 15,202 | 5,255 | 5,362 | 5,986 |
Other Long-Term Assets | 27,121 | 21,301 | 16,881 | 10,742 | 19,511 |
Total Assets | 579,346 | 492,989 | 388,638 | 322,851 | 297,469 |
Accounts Payable | 33,411 | 35,523 | 26,144 | 22,684 | 22,662 |
Short-Term Debt | 59,135 | 38,045 | 12,723 | 11,190 | 27,082 |
Current Portion of Long-Term Debt | 6,003 | 857 | - | - | - |
Current Portion of Leases | - | - | 1,307 | 1,004 | 1,017 |
Other Current Liabilities | 69,017 | 55,967 | 55,706 | 50,843 | 46,897 |
Total Current Liabilities | 167,566 | 130,392 | 95,880 | 85,721 | 97,658 |
Long-Term Debt | 12,203 | 7,864 | 3,800 | - | 3,800 |
Long-Term Leases | - | - | 2,190 | 1,278 | 1,946 |
Other Long-Term Liabilities | 19,120 | 17,567 | 4,220 | 2,991 | 1,941 |
Total Long-Term Liabilities | 31,323 | 25,431 | 10,210 | 4,269 | 7,687 |
Total Liabilities | 198,889 | 155,823 | 106,090 | 89,990 | 105,345 |
Common Stock | 835 | 834 | 834 | 833 | 832 |
Treasury Stock | -1,815 | -2,264 | - | - | - |
Additional Paid-in Capital | 13,048 | 12,775 | - | - | - |
Accumulated Other Comprehensive Income | 8,859 | 2,098 | - | - | - |
Retained Earnings | 356,136 | 319,945 | 281,714 | 232,028 | 191,292 |
Total Common Shareholders' Equity | 377,063 | 333,388 | 282,548 | 232,861 | 192,124 |
Minority Interest | 3,394 | 3,778 | - | - | - |
Shareholders' Equity | 380,457 | 337,166 | 282,548 | 232,861 | 192,124 |
Total Liabilities & Equity | 579,346 | 492,989 | 388,638 | 322,851 | 297,469 |
Total Debt | 77,341 | 46,766 | 20,020 | 13,472 | 33,845 |
Net Cash (Debt) | 10,473 | 11,142 | 41,307 | 48,326 | 10,520 |
Net Cash Growth | -6.00% | -73.03% | -14.52% | 359.37% | 184.32% |
Net Cash Per Share | 12.57 | 13.36 | 49.56 | 58.09 | 12.65 |
Book Value | 377,063 | 333,388 | 282,548 | 232,861 | 192,124 |
Book Value Per Share | 452.48 | 399.66 | 338.97 | 279.90 | 231.00 |
Tangible Book Value | 259,111 | 224,775 | 240,096 | 196,663 | 159,640 |
Tangible Book Value Per Share | 310.93 | 269.46 | 288.05 | 236.39 | 191.95 |